Silence Therapeutics Plc - Amer (SLN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Silence Therapeutics Plc - Amer

NasdaqGM•Healthcare•Biotechnology

$14.59-0.20(-0.01%)Market closed

Market Cap

$1.73B

P/S

2811.2x

P/B

44.9x

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

How this company scores

WeakMetricSide Score: 39/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (6/25).

Profitability6/25

Growth11/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality7/25

Strengths

Interest easily coveredConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 2811.2x5y range 18.4x – 2811.2x

Currently above its 4-quarter median.

P/B · 44.9x5y range 3.5x – 44.9x

Currently above its 7-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 6 of the last 7 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.73B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $615,000
Q. Revenue: $0
TTM EBITDA: $-68.31M
TTM Op. Income: $-68.31M
Q. Op. Income: $-13.87M
TTM Net Income: $-59.95M
Q. Net Income: $-12.27M
EPS: $-0.09
Shares Out.: $141.71M

$615,000 in TTM revenue grew from zero YoY, reaching $0 last quarter. TTM EBITDA of $-68.31M and TTM operating income of $-68.31M show growth is flowing through to the bottom line. However, net income is negative at $59.95M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 0% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -1386500000.0%
Net Margin: -1226800000.0%

Op. margin of -1386500000.0% is down 1386489302.2% YoY — costs are rising relative to revenue. Net margin at -1226800000.0% Over the past year, operating margin is down 12960548% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2811.2x
P/B Ratio: 44.9x

P/S of 2811.2x and P/B of 44.9x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $106.41M
Cash: $72.05M
Long-Term Debt: N/A
Book Value: $38.47M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.52M
TTM Free Cash Flow: $-42.27M
FCF Margin: -6872.5%
FCF / Net Income: 0.7

TTM FCF of $-42.27M on $1.52M in operating cash flow. The FCF / Net Income ratio of 0.7x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 0% — an improving trend.